Impact BioMedical, Inc. (IBO)
3.89
+0.34
(+9.58%)
USD |
NYAM |
Oct 28, 10:37
Impact BioMedical Enterprise Value : 33.57M for Oct. 27, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 27, 2026 | 33.57M |
| October 26, 2026 | 35.10M |
| October 23, 2026 | 33.99M |
| October 22, 2026 | 35.70M |
| October 21, 2026 | 37.58M |
| October 20, 2026 | 31.15M |
| October 19, 2026 | 29.38M |
| October 16, 2026 | 26.13M |
| October 15, 2026 | 30.22M |
| October 14, 2026 | 32.31M |
| October 13, 2026 | 37.24M |
| October 12, 2026 | 37.67M |
| October 09, 2026 | 39.55M |
| October 08, 2026 | 38.35M |
| October 07, 2026 | 41.51M |
| October 06, 2026 | 43.22M |
| October 05, 2026 | 44.59M |
| October 02, 2026 | 48.69M |
| October 01, 2026 | 49.63M |
| September 30, 2026 | 51.08M |
| September 29, 2026 | 51.08M |
| September 28, 2026 | 51.17M |
| September 25, 2026 | 51.85M |
| September 24, 2026 | 51.51M |
| September 23, 2026 | 59.88M |
| Date | Value |
|---|---|
| September 22, 2026 | 60.12M |
| September 21, 2026 | 63.15M |
| September 18, 2026 | 66.85M |
| September 17, 2026 | 64.85M |
| September 16, 2026 | 56.93M |
| September 15, 2026 | 60.27M |
| September 14, 2026 | 55.43M |
| September 11, 2026 | 52.86M |
| September 10, 2026 | 50.79M |
| September 09, 2026 | 56.47M |
| September 08, 2026 | 57.15M |
| September 04, 2026 | 61.46M |
| September 03, 2026 | 54.99M |
| September 02, 2026 | 56.07M |
| September 01, 2026 | 52.62M |
| August 31, 2026 | 52.96M |
| August 28, 2026 | 51.08M |
| August 27, 2026 | 50.79M |
| August 26, 2026 | 50.69M |
| August 25, 2026 | 52.86M |
| August 24, 2026 | 52.08M |
| August 21, 2026 | 54.99M |
| August 20, 2026 | 51.68M |
| August 19, 2026 | 49.94M |
| August 18, 2026 | 53.91M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| LENZ Therapeutics, Inc. | -120.47M |
| Enveric Biosciences, Inc. | -2.707M |
| ANI Pharmaceuticals, Inc. | 1.870B |
| Corcept Therapeutics, Inc. | 9.154B |
| Veru, Inc. | 15.77M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.70M |
| Revenue (Quarterly) | 0.003M |
| Total Expenses (Quarterly) | 0.702M |
| EPS Diluted (Quarterly) | -0.0818 |
| Gross Profit Margin (Quarterly) | -9.40K% |
| Profit Margin (Quarterly) | -23.33K% |
| Earnings Yield | -31.86% |
| Normalized Earnings Yield | -35.16 |